Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21773554 | 0.84 | P2RX7 (0.47) | P2RX7 | |
| SCHEMBL21773553 | 0.84 | P2RX7 (0.47) | P2RX7 | |
| SCHEMBL20489256 | 0.75 | KDM4E (0.35) | P2RX7KDM4ELMNANPSR1GFER | |
| SCHEMBL20489255 | 0.75 | KDM4E (0.35) | P2RX7KDM4ELMNANPSR1GFER | |
| SCHEMBL21791600 | 0.72 | PDE4D (0.35) | P2RX7KDM4ELMNANPSR1GFER | |
| SCHEMBL28347572 | 0.72 | PDE4D (0.35) | P2RX7KDM4ELMNANPSR1GFER | |
| SCHEMBL6559444 | 0.69 | KDM4E (0.48) | P2RX7KDM4ELMNANPSR1GFER | |
| SCHEMBL2918000 | 0.68 | TDP1 (0.45) | CA1CA2CA7CTSS | |
| SCHEMBL2919446 | 0.68 | TDP1 (0.45) | CA1CA2CA7CTSS | |
| SCHEMBL2919444 | 0.68 | TDP1 (0.45) | CA1CA2CA7CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069648-A1 | HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069648-A1 | HALOALLYLAMINE PYRAZOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | LOX, DAO, AADAC | P2RX7 1145/4885KDM4E 647/4885LMNA 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.